Shares of Spyre Therapeutics climbed about 4% on Friday after Deutsche Bank kicked off coverage with a Buy rating and a price target of $43. That target is nearly three times higher than Spyre\u2019s last close at $15.61, signaling strong upside potential in the eyes of analysts.<\/p>\n
Spyre is a young biotech focused on treatments for inflammatory bowel disease, which includes ulcerative colitis and Crohn\u2019s disease. Analyst David Hoang said the company could become a major player in this space thanks to its extended half-life antibodies and fixed-dose combination therapies. These approaches are designed to improve how long treatments work in the body and make it easier for patients to manage their condition.<\/p>\n
Deutsche Bank believes the company\u2019s pipeline is worth far more than its current market value of about $1 billion. If Spyre\u2019s therapies succeed in trials, Hoang estimates peak sales could reach around $5.7 billion. The company is working on both standalone drugs and combination treatments that target proven mechanisms such as \u03b14\u03b27, TL1A, and IL-23, all of which are linked to IBD.<\/p>\n
Hoang also pointed out that Spyre\u2019s TL1A therapies may eventually expand into other conditions like rheumatic diseases, which could open new markets for the company. Beyond its science, timing could be in Spyre\u2019s favor. The IBD drug market has been a hot spot for big pharmaceutical deals, with recent buyouts of Arena, Telavant, Prometheus, and Morphic following encouraging trial results.<\/p>\n
Spyre was born out of Fairmount Funds\u2019 Paragon incubator, with a mission to build better biologic drugs for IBD patients. Friday\u2019s analyst note gave investors more confidence that this small biotech could grow into a significant name in the field if its experimental drugs deliver in clinical trials.<\/p>\n","protected":false},"excerpt":{"rendered":"
Shares of Spyre Therapeutics climbed about 4% on Friday after Deutsche Bank kicked off coverage with a Buy rating and\u2026<\/p>\n","protected":false},"author":294,"featured_media":89082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[32706],"class_list":["post-89081","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-markets","tag-spyre-therapeutics"],"reading_time":"2 min read","_links":{"self":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/89081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/users\/294"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/comments?post=89081"}],"version-history":[{"count":0,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/89081\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media\/89082"}],"wp:attachment":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media?parent=89081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/categories?post=89081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/tags?post=89081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}